Positive Outlook for Achieve Life Sciences: Buy Rating Backed by Promising Regulatory Progress and Market Potential
I'm PortAI, I can summarize articles.
JonesTrading analyst Justin Walsh has reiterated a Buy rating for Achieve Life Sciences (ACHV) stock, citing promising regulatory progress and market potential for its drug cytisinicline, which targets smoking cessation. The FDA has set a PDUFA target action date for the drug, which has shown a favorable safety profile. Additionally, cytisinicline has received a National Priority Voucher from the FDA, indicating potential for expedited review. H.C. Wainwright also maintains a Buy rating with a $12.00 price target, reflecting confidence in the company's future.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments